Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients

Inclusion Criteria: * Men and women 18-65 years of age who are recipients of a renal transplant at least 6 months prior to enrollment * Patients on oral Prograf therapy as part of their maintenance immunosuppression therapy, with stable doses and trough levels of tacrolimus of 7-12 ng/mL for at least two weeks prior to enrollment. * Patients maintained on concurrent immunosuppression with mycophenolate mofetil (MMF, CellCept) or mycophenolic acid delayed-release tablets (Myfortic), with stable doses for at least two weeks prior to enrollment * Patients with serum creatinine \< 2.0mg/dL prior to enrollment * Able to swallow study medication * Patients capable of understanding the purposes and risks of the study, who can give written informed consent and who are willing to participate in and comply with the study * Women of childbearing potential must have a negative serum pregnancy test within seven days prior to receiving study medication * Patients who successfully pass a drug screen Exclusion Criteria: * Recipients of any transplanted organ other than a kidney * White blood cell count \< 2.8 x 10\^9 /L * Patients who are receiving a total dose of Prograf for 24 hours \< 3mg * Patients unable or unwilling to provide informed consent * Pregnant or nursing women * Patients with reproductive potential who are unwilling/unable to use a double barrier method of contraception * Administration of other investigational agent in the three months prior to enrollment * Patient receiving any drug interfering with tacrolimus metabolism * Patients who have taken sirolimus within the past three months prior to screening * Patient with an episode of acute cellular requiring antibody therapy within the 6 months prior to enrollment * Patient treated for acute cellular rejection within the 30 days prior to enrollment * Patient who is HCV negative and has received an HCV positive (HCV RNA by PCR or HCV antibody) donor kidney * Patient has a current malignancy or a history of malignancy (within the past 5 years), except basal or non-metastatic squamous cell carcinoma of the skin that has been treated successfully * Patient has uncontrolled concomitant infection, a systemic infection requiring treatment, or any other unstable medical condition that could interfere with the study objectives * Patient has severe diarrhea, vomiting, active peptic ulcer or gastrointestinal disorder that may affect the absorption of tacrolimus * Patient will require therapy with any immunosuppressive agent other than those prescribed in the study * Patient has a known hypersensitivity to corticosteroids, mycophenolate mofetil, mycophenolic acid or tacrolimus * Patient has any form of current substance abuse, psychiatric disorder or a condition that, in the opinion of the Investigator, may invalidate communication with the Investigator